AndroGel Cost in Nebraska 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is AndroGel and Why Does Cost Vary by State?

AndroGel is a topical testosterone gel approved by the FDA for adult males with hypogonadism, a condition defined by consistently low serum testosterone levels combined with clinical symptoms. The FDA label covers two concentrations: 1% (50 mg/5 g packet or pump) and 1.62% (20.25 mg to 81 mg per pump actuation). Both formulations are manufactured by AbbVie and are Schedule III controlled substances under federal law, which shapes how pharmacies, insurers, and state Medicaid programs handle them. FDA prescribing information for AndroGel is available at accessdata.fda.gov.

State-level cost variation reflects three forces: the pharmacy's negotiated contracts with wholesalers, each state's Medicaid formulary decisions, and the density of retail competition. Nebraska, a largely rural state, has fewer large retail chains in many counties than coastal states, which keeps cash-pay discount competition lower than in, say, Illinois or Colorado. The AbbVie list price is the same nationally at approximately $510 per month, but the out-of-pocket figure a Nebraska patient actually pays depends heavily on their insurance tier and whether they qualify for manufacturer assistance.

The T-Trials, a coordinated set of seven placebo-controlled trials in 788 older men with confirmed hypogonadism, produced the most rigorous evidence base for testosterone-gel therapy to date. Across sub-studies published in the New England Journal of Medicine, testosterone treatment produced statistically significant improvements in sexual function, bone mineral density, and walking distance compared with placebo. Read the primary T-Trials publication at PubMed. Those data helped solidify AndroGel's clinical standing, but they have not persuaded state Medicaid programs like Nebraska's to move the drug onto their formularies.

AndroGel Cash Price in Nebraska in 2026

The full cash price for AndroGel in Nebraska retail pharmacies is approximately $510 per month for a 30-day supply of the 1.62% formulation in 2026. That figure reflects AbbVie's wholesale acquisition cost passed through to the consumer without insurer negotiation or manufacturer rebates. Walk into any Walgreens, Walmart Pharmacy, or independent pharmacy in Omaha, Lincoln, or Kearney without a coupon or insurance, and you will pay somewhere near that number.

GoodRx and similar discount platforms can reduce the cash price to roughly $430 to $480 at select Nebraska locations, depending on the specific zip code and the platform's negotiated rate at that pharmacy. These discounts cannot be stacked with insurance copays under federal anti-kickback rules, so patients must choose one or the other.

The 1% formulation in packet form may price slightly differently than the pump, but the difference is generally under $30 per month at retail. Patients who need cost reduction and cannot qualify for the AbbVie savings program should ask their prescriber whether a different testosterone formulation, such as testosterone cypionate injectable (which can cost as little as $30 to $60 per month through GoodRx in Nebraska), is clinically appropriate for their case.

Does Nebraska Medicaid Cover AndroGel?

Nebraska Medicaid does not cover AndroGel for male hypogonadism. This is a formulary exclusion, not a blanket prohibition on testosterone. Nebraska's Medicaid program does cover generic testosterone cypionate injection for qualifying diagnoses, but brand-name testosterone gels including AndroGel are excluded from the preferred drug list as of 2026.

Patients enrolled in Nebraska Medicaid who need topical testosterone face a prior-authorization path that is rarely approved for the brand product. A prescriber can submit a prior authorization citing documented allergy to injected formulations, needle phobia with clinical documentation, or a specific contraindication to intramuscular administration. Approval rates for these exceptions are not publicly reported by Nebraska DHHS, but clinicians in the state report a high denial rate for brand-name gel specifically.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We suggest against a universal age-specific testosterone reference range and recommend that clinicians measure testosterone levels in men with symptoms and signs of hypogonadism." Full guideline text is available via the Endocrine Society at endocrine.org. That framing supports individualized prescribing, but it does not change Nebraska Medicaid's formulary decision, which is driven by cost-effectiveness analyses rather than clinical complexity.

Medicaid patients in Nebraska who need testosterone replacement have two realistic options: generic injectable testosterone (covered) or a 503A-compounded topical gel paid for out of pocket.

How the AbbVie MyAbbVie Assist and Savings Card Work in Nebraska

AbbVie runs two separate assistance programs that Nebraska patients should know about: the commercial savings card and the patient assistance program (PAP) for uninsured or underinsured patients.

Commercial savings card. Commercially insured Nebraska patients, meaning those covered by private insurance or employer-sponsored plans, can use the AbbVie savings card to pay as little as $0 per month for AndroGel, subject to a monthly cap that AbbVie sets annually. The card functions like a secondary payer: it covers the gap between the insurer's negotiated price and the patient's copay, up to the cap. Patients with high-deductible plans may see the cap limit the benefit during the deductible phase of their plan year. The savings card cannot be used alongside any government-funded insurance, which specifically excludes Medicare Part D, Medicaid, TRICARE, and VA coverage.

Patient assistance program. Uninsured Nebraska patients who meet AbbVie's income eligibility threshold, which the company sets at or below 600% of the federal poverty level for most programs, may qualify for free or deeply discounted AndroGel through the PAP. Applications require income documentation, a prescription, and proof of Nebraska residency. Processing takes two to six weeks, and the drug is typically shipped directly to the prescribing clinician's office or, in some cases, to the patient's home.

Nebraska patients should apply at abbvie.com or call AbbVie at 1-800-222-6885 directly. Telehealth prescribers licensed in Nebraska can also submit PAP paperwork on a patient's behalf in most cases.

Compounded Testosterone Gel in Nebraska: Legality and Pricing

Compounded testosterone gel prepared by a licensed 503A pharmacy is legal in Nebraska. A 503A pharmacy compounds drugs for individual patients based on a valid prescription from a licensed prescriber. Nebraska does not impose additional state-level restrictions beyond federal USP <797> sterile compounding standards (though testosterone gel is a non-sterile preparation governed by USP <795> standards).

The cost advantage is significant. Where branded AndroGel runs approximately $510 per month cash, a compounded testosterone gel from a Nebraska-licensed or nationally operating 503A pharmacy typically costs $80 to $120 per month for a comparable dose. That price often includes a standard concentration of 10 mg/gram or 20 mg/gram in a transdermal gel base, dispensed in a pump or syringe.

The clinical trade-off is real. Compounded products are not FDA-approved. Their potency, sterility, and absorption characteristics are not independently validated the way a brand or generic product is. A 2017 analysis in JAMA Internal Medicine found substantial variability in testosterone concentration among compounded testosterone products tested, with some samples deviating more than 20% from labeled potency. Read the relevant JAMA Internal Medicine report via PubMed. Patients choosing compounded testosterone gel should use a pharmacy with current PCAB (Pharmacy Compounding Accreditation Board) accreditation and should confirm their lab values at 4 to 6 weeks after starting to verify adequate absorption.

503B outsourcing facilities, which produce larger batches without patient-specific prescriptions, are a different regulatory category. Testosterone is not on the FDA's current 503B bulk drug substance list, so 503B-produced testosterone gel for individual patient use is not permitted. Nebraska patients will be using 503A compounded products, not 503B.

HealthRX Nebraska Testosterone Formulation Decision Framework

The HealthRX medical team uses the following four-step logic when advising Nebraska patients on formulation choice. Step one: confirm diagnosis with two morning total testosterone levels below 300 ng/dL plus symptoms. Step two: check insurance. If commercial coverage exists, apply the AbbVie savings card first. Step three: if Medicaid or Medicare, pivot to generic injectable testosterone cypionate as first-line. Step four: if cash pay and needle-averse or unable to self-inject, 503A compounded testosterone gel from a PCAB-accredited pharmacy at $80 to $120 per month is the most cost-effective topical option in Nebraska.

Telehealth Prescribing of AndroGel in Nebraska

Telehealth prescribing of AndroGel is legal in Nebraska as of 2026. A provider licensed in Nebraska may conduct an audio-visual evaluation, review lab results, and issue a Schedule III controlled substance prescription for testosterone gel under Nebraska's telehealth framework, which aligns with the temporary DEA rules extended through 2025 and under continued regulatory review for 2026. Patients do not need to present to a physical office for an initial testosterone prescription in Nebraska, provided the prescriber holds a Nebraska license and follows standard DEA requirements for Schedule III substances.

Two lab values are required before any responsible prescriber initiates testosterone therapy: total testosterone (drawn before 10:00 a.m., confirmed on two separate days) and, at minimum, LH and FSH to differentiate primary from secondary hypogonadism. A CBC, PSA (in men 40 and older), hematocrit, and lipid panel are standard baseline tests. Nebraska telehealth platforms typically route lab orders to Quest Diagnostics or LabCorp locations throughout the state, with draw sites in Omaha, Lincoln, Grand Island, North Platte, and Scottsbluff.

The Endocrine Society guideline specifies: "Before initiating testosterone therapy, clinicians should explain to patients the potential risks of testosterone therapy including... erythrocytosis, worsening of obstructive sleep apnea, and possible impact on fertility." That informed-consent conversation can and does occur via telehealth video visit with equivalent clinical validity as an in-person encounter.

Nebraska telehealth patients should confirm their platform's prescriber holds an active Nebraska DEA registration, not just a state medical license, before starting the process. Without the DEA registration, the Schedule III prescription cannot be issued.

Which Insurance Plans Cover AndroGel in Nebraska?

Coverage varies by plan type, and no single answer applies to all Nebraska residents. Here is a breakdown by coverage category.

Employer-sponsored commercial plans. Most large Nebraska employers (Mutual of Omaha, Nelnet, the University of Nebraska system, and major agricultural employers) use United Healthcare, Cigna, Aetna, or Blue Cross Blue Shield of Nebraska as their carrier. All four carriers have AndroGel on their formularies at Tier 3 or Tier 4 in most plan designs, which produces a copay of $60 to $150 per month before the AbbVie savings card is applied. After the card, most commercially insured patients pay $0 to $30 per month.

ACA Marketplace plans. Nebraska ACA plans offered through healthcare.gov tend to place branded testosterone gels on specialty tiers with high cost-sharing. Silver-tier plans in Omaha and Lincoln typically produce a $90 to $200 per-fill copay for AndroGel before any assistance. The AbbVie savings card applies here, subject to the annual cap.

Medicare Part D. Medicare beneficiaries cannot use the AbbVie savings card. AndroGel appears on some Part D formularies at Tier 4 or Tier 5, producing substantial out-of-pocket costs until the catastrophic coverage threshold is reached. The Medicare Extra Help program (low-income subsidy) can significantly reduce Part D cost-sharing for qualifying Nebraska beneficiaries. For Medicare patients, generic testosterone cypionate injection remains the most cost-effective covered option.

Nebraska Medicaid. As detailed above, AndroGel is not covered. Generic injectable testosterone is covered under Medicaid.

VA and TRICARE. Nebraska veterans receiving care through the Omaha VA Medical Center or the Grand Island VA clinic have access to testosterone therapy through the VA formulary, which includes testosterone cypionate injection and, in some cases, topical testosterone through VA-contracted compounding or generic channels. TRICARE formulary placement of AndroGel varies by plan year.

Monitoring Costs and Total Treatment Budget in Nebraska

The drug price is only part of the monthly cost. Nebraska patients on AndroGel should budget for the following additional expenses.

Lab monitoring: testosterone levels should be checked at 3 to 6 months after starting, then annually once stable. A testosterone panel through LabCorp or Quest in Nebraska costs $30 to $90 cash pay, or is covered under most commercial plans as a diagnostic test. Hematocrit should be checked at the same intervals given the FDA boxed-warning risk of polycythemia. In the T-Trials, 5.9% of testosterone-treated participants developed hematocrit greater than 54%, compared with 1.0% in the placebo arm, a clinically meaningful difference that mandates routine monitoring. See the T-Trials primary publication.

PSA monitoring in men 40 and older: once annually, or more frequently if baseline PSA is elevated. A PSA test runs $20 to $50 cash pay in Nebraska.

Prescriber visits: Nebraska telehealth follow-up visits for testosterone management typically cost $50 to $150 per visit, with two to four visits per year recommended in the first year. Many commercial plans cover telehealth follow-up at the standard specialist copay.

The all-in monthly cost for a Nebraska cash-pay patient using branded AndroGel, averaged across a full 12 months of monitoring, lands near $560 to $620 per month when labs and visits are included. For a commercially insured patient with the AbbVie savings card, total out-of-pocket typically falls to $80 to $160 per month including labs and visits. For a 503A compounded-gel patient paying cash, total costs average $160 to $220 per month including compounding pharmacy fees, labs, and telehealth visits.

Application Site Risks and Why They Matter for Nebraska Rural Patients

One under-discussed cost driver is transfer contamination. AndroGel and all topical testosterone products carry an FDA boxed warning about secondary exposure to women and children through skin contact. Patients who work in agriculture, childcare, or close-contact occupations must apply gel to sites covered by clothing, allow complete drying (3 to 5 minutes), and wash hands immediately after application. Secondary exposure has produced virilization in female partners and children, documented in FDA adverse event reports as early as 2009.

Rural Nebraska patients, where multi-generational households and farm work are common, need explicit counseling on this risk. The FDA label states the application sites must be allowed to dry before contact and that clothing should cover the area before any skin-to-skin contact with another person. Full FDA label language is available at accessdata.fda.gov. For patients in high-contact situations, testosterone cypionate injection eliminates the transfer risk entirely and may be a safer formulation choice regardless of cost.

Comparing AndroGel to Other Testosterone Formulations Available in Nebraska

Nebraska-licensed prescribers can offer several testosterone formulations. Understanding where AndroGel sits relative to alternatives helps patients make cost-effective decisions.

Testosterone cypionate (generic injectable): $30 to $60 per month cash, covered by Nebraska Medicaid, weekly or biweekly self-injection. Most cost-effective option with the longest evidence record.

Testosterone enanthate (generic injectable): similar pricing to cypionate, slightly longer half-life, biweekly injection typical.

AndroGel 1.62% (brand): $510 list, $0 to $60 with savings card on commercial insurance, daily topical application.

AndroGel 1% (brand): slightly different pricing structure, otherwise similar.

503A compounded testosterone gel (non-FDA-approved): $80 to $120 per month, daily application, variable potency.

Testosterone patches (Androderm): typically $250 to $400 per month after discounts, daily application, higher rate of skin irritation than gel.

Testosterone nasal gel (Natesto): narrower indication, three-times-daily dosing, roughly $400 per month, preserves fertility axis better than other formulations because it does not suppress LH as severely.

Testosterone pellets (Testopel): $500 to $800 per insertion procedure, every 3 to 6 months, administered in-office, not self-administered.

For most Nebraska patients with commercial insurance, AndroGel with the AbbVie savings card is price-competitive with alternatives once the savings card brings the copay to $0 to $30 per month. For cash-pay patients and Medicaid patients, generic injectable testosterone is the financially dominant choice unless there is a specific contraindication to injection.